Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
CEO | Dr. Thomas J. Schuetz M.D., Ph.D. |
IPO Date | April 5, 2021 |
Location | United States |
Headquarters | 80 Guest Street, Boston, MA, United States, 02135 |
Employees | 32 |
Sector | Healthcare |
Industry | Biotechnology |
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
NA
NA
NA
NA
NA
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email